Analyst firms · Oppenheimer · NTLA
Oppenheimer NTLA price target and rating history
Intellia Therapeutics Inc. (NTLA) · Health Care
Oppenheimer rates Intellia Therapeutics Inc. (NTLA) Outperform with a $150 price target, as of its latest action on Feb 7, 2022. It has published 4 rating actions on NTLA since June 2021, including 1 upgrade and 0 downgrades.
- Current rating
- Outperform
- Price target
- $150
- Median target, all firms
- Too few
- Actions on NTLA
- 4
Oppenheimer price target on NTLA
Every Oppenheimer rating on NTLA
- Feb 7, 2022
- Nov 5, 2021
- Aug 6, 2021
- Jun 29, 2021
How other firms rate NTLA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Underweight | $8 | Oct 6, 2026 |
| Wolfe Research | Underperform | $9 | Jul 16, 2026 |
| William Blair | Outperform | Mar 2, 2026 |
Questions about Oppenheimer and NTLA
- What is Oppenheimer's price target for NTLA?
- Oppenheimer's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $150, from its action on Feb 7, 2022.
- What is Oppenheimer's rating on NTLA?
- Oppenheimer rates NTLA Outperform, a bullish rating, as of Feb 7, 2022.
- When did Oppenheimer last change its view on NTLA?
- On Feb 7, 2022, Oppenheimer upgrades to Outperform from Perform, price target $145 to $150.
More NTLA rating histories
All Oppenheimer ratingsNTLA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.